Array BioPharma (NASDAQ: ARRY)announced on Tuesday that it has entered into a clinical trial collaboration agreement with Pfizer (NYSE: PFE) to study the safety and efficacy of novel anti-cancer combinations.
The combinations include Array’s MEK inhibitor, binimetinib with Pfizer's investigational PARP inhibitor talazoparib and avelumab, a human anti-PD-L1 IgG1 monoclonal antibody.
Through the collaboration, Array and Pfizer hope to explore the potential benefits of combining molecularly targeted therapeutics with the body’s innate cancer-fighting abilities using immunotherapy, according to the statement.
"Array is excited to announce this partnership with Pfizer, an established global leader in Oncology therapeutics," said Ron Squarer, Chief Executive Officer, Array BioPharma. "These novel approaches combining targeted therapy and immunotherapy hold great potential to help patients fighting cancer in different indications, with an initial main focus on lung and pancreatic cancer."
Under the agreement, Array and Pfizer will collaborate on a Phase 1b clinical trial to explore a series of novel combinations. Initially, the focus will be in non-small cell lung cancer and pancreatic cancer, and then additional trials at later stages.
The trial will be sponsored and funded by Pfizer, with Array supplying binimetinib. The study is expected to begin in the third quarter of 2018.